Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials.
Ruth SimChong Chun WieNavin Kumar LoganadanAlan Yean-Yip FongLeenhapong NavaravongZanariah HusseinKamlesh Khunti F MedSciDr Shaun Wen Huey LeePublished in: Diabetic medicine : a journal of the British Diabetic Association (2022)
SGLT2i and GLP1RA were associated with lower risk for different cardiorenal end points, when used as an adjunct to metformin in people with type 2 diabetes. Additionally, SGLT2i demonstrated benefits in reducing risk for surrogate end points in kidney disease progression. Safety outcomes differ among the available pharmacotherapies.